Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Laser Moxibustion Appears to Lessen Cancer-Related Fatigue

August 10, 2016
By Dave Levitan
Article

An infrared laser-based version of the traditional Chinese medicinal technique known as moxibustion was found to improve cancer-related fatigue.

An infrared laser-based version of the traditional Chinese medicinal technique known as moxibustion was found to improve cancer-related fatigue compared to a sham version of the technique in a new randomized study.

“Clinical treatments of cancer-related fatigue have been unsatisfactory, without recognized and effective drug treatments,” wrote study authors led by Xueyong Shen, MD, of the Shanghai University of Traditional Chinese Medicine. Moxibustion involves burning of an herb known as moxa on or above the skin at acupoints; there have been few high-quality studies done on this technique, though it has been used for thousands of years to treat a variety of conditions.

In the new study, the researchers used a version of moxibustion involving a 10.6 µm infrared laser, which they wrote mimics the effects of traditional moxibustion but eliminates some of its shortcomings including smoke and dosage control difficulties. The trial included 78 patients (61 of whom completed the full study) with cancer-related fatigue; patients were randomized to either three 20-minute sessions per week for 4 weeks or a sham version of the same treatments, without infrared laser output. The results were published online ahead of print in Cancer.

There were 30 patients in the moxibustion group and 31 in the sham group available for analysis. At baseline, cancer-related fatigue as measured using the Brief Fatigue Inventory was similar between the groups (4.67 in the laser group and 5.03 in the sham group; P = .407).

By week 2 of the study, fatigue scores had dropped to 3.80 in the moxibustion group, compared with 4.70 in the sham group (P = .044). At the end of the 4 weeks of treatment, the difference was more pronounced, at 3.01 vs 4.40 (P = .002). The difference remained at an 8-week follow-up visit as well, at 3.03 vs 4.26 (P = .006).

The authors reported no serious adverse events in either group. Three patients in the laser group had localized erythema, though this resolved within 3 days.

“The findings of the current study suggest that 10.6-μm infrared laser moxibustion holds therapeutic potential as a potentially safe and effective non-pharmacological intervention for cancer-related fatigue,” they concluded. The study was limited by its small size, the significant dropout rate mostly related to worsening condition of the patients, the lack of long-term follow-up, and no usual-care group for comparison.

The authors wrote that longer studies are needed to confirm the benefit of the treatment, as is further research to elucidate what the mechanism behind the clinical effect might be.

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Related Content
Advertisement

Novel Microbiome-Based Therapy Safe, Tolerable in GI-aGVHD

Novel Microbiome-Based Therapy Safe, Tolerable in GI-aGVHD

Andrea Eleazar, MHS
December 9th 2025
Article

The primary end point of GI overall response rate was met with MaaT013 for GI-aGVHD.


Why Sexual and Gender Minority Care is an Oncologic Imperative

Why Sexual and Gender Minority Care is an Oncologic Imperative

Daniel C. McFarland, DO;Charles S. Kamen, PhD, MPH
December 8th 2025
Podcast

Daniel C. McFarland, DO, and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.


Data from a phase 1/2 trial support sonrotoclax as a promising treatment option in previously treated relapsed/refractory mantle cell lymphoma.

Sonrotoclax Elicits Responses in Relapsed/Refractory Mantle Cell Lymphoma

Kyle Doherty
December 8th 2025
Article

Data from a phase 1/2 trial support sonrotoclax as a promising treatment option in previously treated relapsed/refractory mantle cell lymphoma.


Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.


MARIPOSA Final OS Results in Asia Population Yield Meaningful Improvement in EGFR NSCLC

MARIPOSA Final OS Results in Asia Population Yield Meaningful Improvement in EGFR NSCLC

Ariana Pelosci
December 8th 2025
Article

In the amivantamab/lazertinib arm, the median OS in the Asian population was not reached vs 38.4 months in the osimertinib arm for patients with EGFR-mutated NSCLC.


Among patients with NPM1-mutated and KMT2A-rearranged disease, respectively, the ORR was 65% and 41% in the phase 1 KOMET-007 trial.

Ziftomenib Combo Exhibits Tolerability/Early Activity in NPM1/KMT2A+ AML

Roman Fabbricatore
December 8th 2025
Article

Among patients with NPM1-mutated and KMT2A-rearranged disease, respectively, the ORR was 65% and 41% in the phase 1 KOMET-007 trial.

Related Content
Advertisement

Novel Microbiome-Based Therapy Safe, Tolerable in GI-aGVHD

Novel Microbiome-Based Therapy Safe, Tolerable in GI-aGVHD

Andrea Eleazar, MHS
December 9th 2025
Article

The primary end point of GI overall response rate was met with MaaT013 for GI-aGVHD.


Why Sexual and Gender Minority Care is an Oncologic Imperative

Why Sexual and Gender Minority Care is an Oncologic Imperative

Daniel C. McFarland, DO;Charles S. Kamen, PhD, MPH
December 8th 2025
Podcast

Daniel C. McFarland, DO, and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.


Data from a phase 1/2 trial support sonrotoclax as a promising treatment option in previously treated relapsed/refractory mantle cell lymphoma.

Sonrotoclax Elicits Responses in Relapsed/Refractory Mantle Cell Lymphoma

Kyle Doherty
December 8th 2025
Article

Data from a phase 1/2 trial support sonrotoclax as a promising treatment option in previously treated relapsed/refractory mantle cell lymphoma.


Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.


MARIPOSA Final OS Results in Asia Population Yield Meaningful Improvement in EGFR NSCLC

MARIPOSA Final OS Results in Asia Population Yield Meaningful Improvement in EGFR NSCLC

Ariana Pelosci
December 8th 2025
Article

In the amivantamab/lazertinib arm, the median OS in the Asian population was not reached vs 38.4 months in the osimertinib arm for patients with EGFR-mutated NSCLC.


Among patients with NPM1-mutated and KMT2A-rearranged disease, respectively, the ORR was 65% and 41% in the phase 1 KOMET-007 trial.

Ziftomenib Combo Exhibits Tolerability/Early Activity in NPM1/KMT2A+ AML

Roman Fabbricatore
December 8th 2025
Article

Among patients with NPM1-mutated and KMT2A-rearranged disease, respectively, the ORR was 65% and 41% in the phase 1 KOMET-007 trial.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.